Literature DB >> 26290479

Neonatal drug withdrawal syndrome: cross-country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada.

Hilary Davies1, Ruth Gilbert2, Kathryn Johnson3, Irene Petersen1, Irwin Nazareth1, Melissa O'Donnell4, Astrid Guttmann5, Arturo Gonzalez-Izquierdo6.   

Abstract

OBJECTIVES: We determined trends over time in the prevalence of neonatal drug withdrawal syndrome (NWS) in England compared with that reported in the USA, Western (W) Australia and Ontario, Canada. We also examined variation in prevalence of NWS according to maternal age, birth weight and across the English NHS by hospital trusts. DESIGN AND
SETTING: Retrospective study using national hospital administrative data (Hospital Episode Statistics) for the NHS in England between 1997 and 2011. NWS was identified using international classification of disease codes in hospital admission records. We searched the research literature and contacted researchers to identify studies reporting trends in the prevalence of NWS. MAIN OUTCOME MEASURES: Prevalence of NWS by calendar year per 1000 live births for each country/state. For births in England, prevalence by maternal age group and birth weight group. Prevalence by NHS trust and region at birth, and funnel plot to show outlying English NHS hospital trusts (>3 SD of mean prevalence). MAIN
RESULTS: Mean prevalence rates of recorded NWS increased in all four countries. Rates stabilised in England and W. Australia from the early 2000s and rose steeply in the USA and Ontario during the late 2000s. The most recent prevalence rates were 2.7/1000 live births in England (2011; 1544 cases); 2.7/1000 in W. Australia (2009); 3.6/1000 in the USA (2009) and 5.1/1000 in Ontario (2011). The highest prevalence in England was among babies born to mothers aged 25-34 years at delivery and among babies born with low birth weight (1500-2500 g). In England in 2011, 8.6% of hospital trusts had a recorded prevalence outside 3 SD of the overall average (7% above, 1% below). The North East region of England had the highest recorded prevalence of NWS.
CONCLUSIONS: Although recorded NWS is stable in England and W. Australia, rising rates in the USA and Ontario may reflect better recognition and/or increased use of prescribed opiate analgesics and highlight the need for surveillance. The extent to which different prevalence rates by hospital trust reflect variation in occurrence, recognition or recording requires further investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Drug Abuse; Drug Withdrawal

Mesh:

Year:  2015        PMID: 26290479     DOI: 10.1136/archdischild-2015-308948

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  20 in total

1.  Positive Predictive Value of Administrative Data for Neonatal Abstinence Syndrome.

Authors:  Faouzi I Maalouf; William O Cooper; Shannon M Stratton; Judith A Dudley; Jean Ko; Anamika Banerji; Stephen W Patrick
Journal:  Pediatrics       Date:  2018-12-04       Impact factor: 7.124

Review 2.  The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.

Authors:  Jason R Pryor; Faouzi I Maalouf; Elizabeth E Krans; Robert E Schumacher; William O Cooper; Stephen W Patrick
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2017-01-10       Impact factor: 5.747

Review 3.  Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.

Authors:  Erin Kelty; David B Preen
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

4.  Prenatal opioid exposure heightens sympathetic arousal and facial expressions of pain/distress in term neonates at 24-48 hours post birth.

Authors:  Christiana N Oji-Mmuo; Rebecca R Speer; Fumiyuki C Gardner; Megan M Marvin; Alexia C Hozella; Kim K Doheny
Journal:  J Matern Fetal Neonatal Med       Date:  2019-04-09

5.  Analysis of the factors that influence the Finnegan Neonatal Abstinence Scoring System.

Authors:  E Gomez-Pomar; A Christian; L Devlin; K T Ibonia; V A Concina; H Bada; P M Westgate
Journal:  J Perinatol       Date:  2017-04-06       Impact factor: 2.521

6.  Relation between opioid-related harms and socioeconomic inequalities in Ontario: a population-based descriptive study.

Authors:  Zoe F Cairncross; Jeremy Herring; Trevor van Ingen; Brendan T Smith; Pamela Leece; Brian Schwartz; Karin Hohenadel
Journal:  CMAJ Open       Date:  2018-10-18

7.  Sedatives for opioid withdrawal in newborn infants.

Authors:  Angelika Zankl; Jill Martin; Jane G Davey; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2021-05-18

8.  Non-pharmacological care for opioid withdrawal in newborns.

Authors:  Adrienne Pahl; Leslie Young; Madge E Buus-Frank; Lenora Marcellus; Roger Soll
Journal:  Cochrane Database Syst Rev       Date:  2020-12-21

9.  Opioid treatment for opioid withdrawal in newborn infants.

Authors:  Angelika Zankl; Jill Martin; Jane G Davey; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2021-07-07

10.  A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey.

Authors:  Lauren E Kelly; Lauren M Jansson; Wendy Moulsdale; Jodi Pereira; Sarah Simpson; Astrid Guttman; Karel Allegaert; Lisa Askie; Henry Roukema; Thierry Lacaze; Jonathan M Davis; Loretta Finnegan; Paula Williamson; Martin Offringa
Journal:  Trials       Date:  2016-11-08       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.